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Bisphosphonates are commonly prescribed to prevent and treat bone loss, but a growing body of 
evidence suggests that bisphosphonates may also have direct and indirect antitumor effects. 
A few previous studies have observed a lower risk of developing a first primary breast cancer 
associated with bisphosphonate use.  Recently, postdoctoral fellow Genevieve Monsees and 
colleagues from the Public Health Sciences Division conducted a population-based nested case-
control study to examine the relationship between bisphosphonate use and risk of contralateral 
breast cancer among women with a first, primary estrogen receptor-positive(ER+) breast cancer. 
Compared to the risk of being diagnosed with a first primary breast cancer for women in the general 
population, breast cancer survivors have a two to six times greater risk of developing a second 
primary breast cancer in their opposite-side breast. 
In a total sample of 1013 women (351 cases with contralateral breast cancer and 662 unilateral 
breast cancer controls), those who had ever used bisphosphonates for 6 months or longer following 
their first breast cancer diagnosis had nearly a 50% lower risk of contralateral breast cancer 
compared with women who had never used bisphosphonates. A longer duration of bisphosphonate 
use, as well as current use, were associated with a further reduced risk. Alendronate was the most 
commonly used agent, used by 88% of bisphosphonate users. 
With more research bisphosphonate therapy could become a feasible strategy for reducing the risk 
of a second primary breast cancer among ER+ breast cancer survivors. The potential antitumor 
effects of these agents outside of the adjuvant setting will be an interesting area for further 
investigation. 
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